canvuparatide
·Code: MBX 2109
canvuparatide: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| MBX Biosciences, Inc. (MBX) | Phase 2 |
FDA Decisions
FDA_MeetingThe Company plans to advance once-weekly canvuparatide into a Phase 3 trial for the treatment of chronic hypoparathyroidism in the third quarter of 2026 based on FDA feedback.(MBX)
Frequently asked questions
Who is developing canvuparatide?
canvuparatide is being developed by MBX Biosciences, Inc..
What is canvuparatide's latest FDA decision?
The most recent tracked FDA decision for canvuparatide is FDA_Meeting for The Company plans to advance once-weekly canvuparatide into a Phase 3 trial for the treatment of chronic hypoparathyroidism in the third quarter of 2026 based on FDA feedback., dated March 9, 2026.
Get deeper analysis on canvuparatide
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis